Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Dec
02
Today In Oncology
Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups
Outcomes Associated With Consensus Molecular Subtypes in First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer
Addition of Pirfenidone to Glucocorticoids in Grade 2 or 3 Radiation-Induced Lung Injury
Lung Cancer Screening Criteria NELSON vs PLCOm2012
ADCs vs Standard Chemotherapy: Cardiotoxicity in HER2-Positive Advanced Breast Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo